SHINE Technologies Donates Doses of its Cancer Therapy to Patients in Need through New Collaboration with the Oncidium Foundation

The two organizations join forces to improve global access to radiopharmaceutical therapy, with the Oncidium foundation aiming to provide 2,000 doses in five years through the initiative

JANESVILLE, Wis., and HAMBURG, Germany, Oct. 17, 2024 /PRNewswire/ -- SHINE Technologies, a next-generation fusion company, today announced a collaboration with the Oncidium foundation, a non-profit organization dedicated to improving global access to radiopharmaceuticals. As part of the collaboration, SHINE is donating doses of Ilumira, its non-carrier added lutetium-177 chloride, to cancer patients in under-resourced countries in need of radiopharmaceutical therapy.

The Oncidium foundation is a non-profit and public benefit organization dedicated to raising awareness about Radiotheranostics for cancer care and providing support to accelerate global access.